Lifeboat Foundation: Safeguarding Humanity
Toggle light / dark theme

Blog

Category: biotech/medical – Page 75

Two classes of FOXA1 mutations found to drive prostate cancer and therapy resistance

A new study from the University of Michigan Rogel Health Cancer Center, published in Science, sheds light on how two distinct classes of mutations in the FOXA1 gene—commonly altered in prostate cancer—drive tumor initiation formation and therapeutic resistance.

FOXA1, a key transcription factor that facilitates binding to DNA, is mutated in 10–40% of hormone-dependent prostate cancers. While common, the exact ways these mutations alter cancer cells have remained elusive—until now.

Rogel researchers, including Arul Chinnaiyan, M.D., Ph.D., S.P. Hicks Endowed Professor of Pathology and Urology, and Abhijit Parolia, Ph.D., Rogel Fellow and Assistant Professor of Pathology, used mouse models to understand the mechanisms underlying two major classes of FOXA1 mutations.

The ‘mind-bending’ bionic arm powered by AI

I was born without lower arms and legs, so I’ve been around prosthetics of all shapes and sizes for as long as I can remember.

I’ve actively avoided those designed for upper arms for most of my adult life, so have never used a bionic hand before.

But when I visited a company in California, which is seeking to take the technology to the next level, I was intrigued enough to try one out — and the results were, frankly, mind-bending.

Prosthetic limbs have come a long way since the early days when they were fashioned out of wood, tin and leather.

Modern-day replacement arms and legs are made of silicone and carbon fibre, and increasingly they are bionic, meaning they have various electronically controlled moving parts to make them more useful to the user. (Feb 2024)

BBC Click reporter Paul Carter tries out a high-tech prosthetic promising a ‘full range of human motion’

Continue reading “The ‘mind-bending’ bionic arm powered by AI” | >

Scientists Finally “See” Key Protein That Controls Inflammation

Researchers used advanced microscopy to uncover important protein structures. For the first time, two important protein structures in the human body are being visualized, thanks in part to cutting-edge technology at the University of Cincinnati’s Center for Advanced Structural Biology. This break

Autosomal Recessive Cerebellar Ataxia-27 Caused by a Novel Loss-of-Function Variant of Ganglioside-Induced Differentiation Associated Protein 2 in a Spanish Family

Question Are there more effective systemic treatment options for ERBB2-negative metastatic breast cancer and active brain metastases?

Findings In this nonrandomized clinical trial of 47 patients treated with utidelone plus bevacizumab, the central nervous system objective response rate was 42.6% according to the Response Evaluation Criteria in Solid Tumors version 1.1. The safety profile of this treatment approach was manageable.

Meaning These findings suggest that combination therapy with utidelone plus bevacizumab is a potentially viable treatment for patients with ERBB2-negative metastatic breast cancer and active brain metastases.

How a faulty transport protein in the brain can trigger severe epilepsy

Citrate is essential for the metabolism and development of neurons. A membrane transport protein called SLC13A5 plays a central role in this process and has previously been linked to a particularly severe form of epileptic encephalopathy.

Building on data from the recently completed RESOLUTE and REsolution flagship projects, scientists at CeMM have comprehensively studied the function and structure of the membrane transporter SLC13A5, experimentally investigating 38 mutant variants.

Their findings, published in Science Advances, shed new light on the mechanisms of this disease and lay the foundation for further research into epilepsy and other disorders.

How the brain links unrelated events: New insights into the amygdala’s role in decision-making

Our brain makes decisions based on direct associations between stimuli in our environment, but it often also does so based on events that initially appear unrelated. How does it achieve this? A recent study by the Cellular Mechanisms in Physiological and Pathological Behavior Research Group at the Hospital del Mar Research Institute, published in Proceedings of the National Academy of Sciences, offers new insights into this process and identifies the brain areas involved.

Using observations in , led primarily by first author and Ph.D. student José Antonio González Parra and supervised by Dr. Arnau Busquets, the research team was able to determine the mechanisms involved in how the brain makes decisions based on indirect associations between different . That is, instead of directly associating a specific stimulus with a rewarding or aversive situation, the brain establishes connections between two or more stimuli.

Dr. Busquets explains, “The project aims to understand how the brain enables us to make decisions based on indirect relationships between stimuli in our environment.”

Injury to specific brain connections could explain some people’s criminal behavior, study finds

Over the past decades, some lawyers have started using brain imaging scans as evidence during criminal trials, to provide a possible explanation for the criminal behavior of defendants. This was justified by recent neuroscientific studies, which found that some people who commit crimes present differences in specific parts of the brain. Yet a key question remains: are these brain changes causal, compensatory or incidental to the behavior?

To answer this question, researchers at Brigham and Women’s Hospital, Harvard Medical School and other institutes in the U.S. analyzed the locations of brain injury temporally associated with a new onset of criminality.

They found evidence suggesting that lesions to a specific white matter tract could be causally implicated in the behavior of individuals who start committing crimes after injury.

SGLT-2 Inhibitors and Serious Liver Events in Patients With Cirrhosis

This retrospective cohort study was conducted using data from TriNetX, a multi-institutional health research network. Using the TriNetX platform, we accessed deidentified electronic health records from over 212 million patients across 120 major health care organizations.9 The built-in analytic functions of TriNetX enable patient-level analyses while ensuring that only population-level data are reported.

This study was approved by WCG Clinical, which granted a waiver to TriNetX as a federated network and was deemed exempt from informed consent owing to the use of existing, non–human participant data that were deidentified per the US Health Insurance Portability and Accountability Act privacy rule. The study followed the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) reporting guideline.

We included patients with cirrhosis (International Statistical Classification of Diseases and Related Health Problems, Tenth Revision [ICD-10] codes K74.6 and K74.69), who were taking furosemide (RxNorm [National Library of Medicine] code 4603) and spironolactone (RxNorm code 9997) between January 2013 and July 2021. For patients receiving an SGLT-2 inhibitor (Anatomical Therapeutic Chemical code A10BK), the index event was defined as the date on which they were concurrently prescribed spironolactone, furosemide, and an SGLT-2 inhibitor. For the control group, the index event was the date on which they were prescribed concurrent spironolactone and furosemide but not an SGLT-2 inhibitor. Each patient was followed up for 3 years from the index event, with follow-up ending on July 11, 2024.

/* */